Alzheimer’s Disease Reversed in Animal Models, Offering Hope for Future Treatments

For over a century, Alzheimer’s disease has been considered an irreversible illness. Now, groundbreaking research challenges that dogma, demonstrating the potential to not only slow or prevent the disease but to actually reverse its effects in animal models. Two independent studies, published in December 2025, reveal that restoring the brain’s energy balance can lead to both pathological and functional recovery, even in advanced stages of the disease.

The Energy Crisis in Alzheimer’s Disease

Researchers at Case Western Reserve University, University Hospitals, and the Cleveland VA Medical Center, led by Kalyani Chaubey from the Pieper Laboratory, identified a critical factor in the development of Alzheimer’s: a decline in the brain’s levels of nicotinamide adenine dinucleotide (NAD+). This central cellular energy molecule is crucial for maintaining proper brain function, and its depletion appears to be a major driver of the disease. The study, published in Cell Reports Medicine, showed that maintaining proper NAD+ balance could prevent and even reverse Alzheimer’s in mouse models.

Restoring Cognitive Function in Mice

The research team tested the effects of P7C3-A20, an experimental drug designed to protect stressed brain cells, on two different mouse strains engineered to develop Alzheimer’s-like symptoms. One strain accumulated amyloid plaques, while the other developed tau tangles – both hallmarks of the disease in humans. Remarkably, the treatment restored cognitive function in both strains, even after symptoms had develop into severe.

In a separate study, published in Cell Reports Medicine, researchers found that P7C3-A20 also reverses advanced disease in tau-driven PS19 mice and protects human brain microvascular endothelial cells from oxidative stress.

Beyond Plaque Removal: A Novel Approach

Current FDA-approved Alzheimer’s drugs, such as lecanemab and aducanumab, focus on removing amyloid plaques from the brain. While these drugs can slow cognitive decline, they do not restore lost memory or cognitive function. The new research takes a different approach, aiming to revitalize the brain’s memory circuitry by addressing the underlying energy imbalance. As Dr. Istvan Mody of UCLA Health explains, “There is really nothing like this on the market or experimentally that has been shown to do this.”

Repairing Brain Damage and Restoring Barriers

The treatment with P7C3-A20 led to several key improvements in the brains of the treated mice. The blood-brain barrier, which protects the brain from harmful substances, was restored after becoming leaky in the diseased animals. Researchers also observed less DNA damage and reduced neuroinflammation. Biomarkers associated with Alzheimer’s-related brain damage decreased in the blood, providing a potential way to track the disease’s progression and response to treatment.

Human Brain Tissue Shows Similar Patterns

Analysis of human brain tissue revealed similar patterns to those observed in the mouse models. Worse Alzheimer’s damage correlated with greater NAD+ imbalance, and patterns of gene expression appeared healthier in individuals who had plaques but remained cognitively sharp. Dozens of proteins changed in both species, and the drug normalized 46 of them in mice, with similar patterns observed in human samples.

Future Directions and Clinical Trials

While these findings are promising, it’s crucial to note that they were obtained in animal models. The next step is to translate these results into human clinical trials to determine whether restoring NAD+ balance can improve memory and cognitive function in people with Alzheimer’s disease. Researchers emphasize the necessitate for careful trial design, tracking blood signals linked to brain damage and assessing cognitive improvements. Self-treating with NAD+ boosting supplements, such as nicotinamide riboside, is not recommended, as some studies have shown potential adverse effects, such as increased cancer spread to the brain in mice.

Key Takeaways

• Alzheimer’s disease may be reversible, at least in animal models, by restoring the brain’s energy balance.
• A decline in NAD+ levels appears to be a critical factor in the development of Alzheimer’s disease.
• The experimental drug P7C3-A20 showed promise in reversing cognitive impairment and repairing brain damage in mice.
• Human brain tissue studies support the findings from animal models.
• Clinical trials are needed to determine whether these findings translate to humans.